You are on page 1of 34

Subject: Submission of a business plan on Handicraft Export to North America and

Europe
international business

| 1
| 2
Year of Establishment

Commercial Production

Status

Type of Business

Product Categories

Dosage Forms

Number of Employees

Export Activities

Principal Office Factory

| 3
| 4
VISION

MISSION

OBJECTIVE

| 5
THE JOURNEY

| 6
1986

1990

1998

2000

2001

2002

2003

2004

2005

| 7
2006

And the journey continue ... ..

| 8
| 9
R&D

| 10
MARKETING

PRODUCT MANAGEMENT DEPARTMENT (PMD)

SALES DEPARTMENT

DISTRIBUTION DEPARTMENT

MEDICAL SERVICES DEPARTMENT (MSD)

SALES TRAINING DEPARTMENT

MARKET RESEARCH TEAM (MRT)

| 11
COMPETITIVENESS

| 12
Manufacturing Cost.
Workforce Skills.
Government and Regulatory Environment.
Macro Factors.

| 13
| 14
Export-led improvement.

Regulatory-led quality improvement.


Competition-led improvement.
Private sector-led improvement.
Knowledge-transfer-led improvement.

| 15
Countries where ARISTOPHARMA products are exported
Singapore
Hong Kong
Sri Lanka
Vietnam
Myanmar
Bhutan
Macau
Ukraine
Mauritius

| 16
WHY EXPORT

PHARMACEUTICAL
PRODUCTS?

| 17
Regulated:

Moderately Regulated:

Unregulated:

| 18
Table 2: Recent Exports by Some Bangladeshi Pharmaceutical Firms

Company Export (USD)


Novartis / Sandoz 12,820,162
Beximco Pharmaceuticals 1,400,000
Square Pharmaceuticals 1,200,000
Aristopharma 733,721
Jams Pharmaceuticals 726,546
Jayson Pharmaceuticals 600,000
The Acme Laboratory Co 331,876
Eskayef Bangladesh 305,648
Renata 281,788
Navana Pharmaceuticals 240,175
Aventis 223,999
ACI 156,392
Essential Drug Co 124,687
Globe Pharmaceuticals 68,410
Opsonin Pharmaceuticals 34,109

| 19
| 20
Heating, ventilation and air-conditioning (HVAC) systems to ensure no
crosscontamination.

Warehouse.

Validation documentation.

Is Russia a favorable destination?


Russia: Country Profile

Location:

| 21
Climate:

Natural Resources and Industries:

Economy

Government and Politics:

Foreign Relations:

Transportation:

Population

Education:

| 22
Health:

Religion:

Ethnic Groups:

Culture:

| 23
Strength

Quality:

Low Price:

Human Resource:

Facilities:

Weaknesses

Lack of skilled workforce:

Corruption:
Political Condition:
Port:
Opportunity
Demand for Imported Pharmaceutical Products:

Cost of Production:

Threats

| 24
Competitors
New possible policies

Corruption:

Nationalists Views:
Counterfeit medicines:

| 25
| 26
Marketing Objectives:
Target Market:
Expected Sales:
Profit Expectations:
Market Penetration and coverage:
Product adaptation or modification
Core Component:
Packaging Component:
Support Service Component:
Promotion Mix

Advertising

Sales promotion:

Personal selling :

Distribution

| 27
Port selection

Mode Selection
Packing

Documentation Required

Insurance Claim
Freight Forwarder

CHANNELS OF DISTRIBUTION
Figure: Distribution channel
Distributor
PRICE DETERMINATION

Drugstores Drugstores Public & Private Health


Sectors
Transportation Costs:
Retailer/pharmacy Public & Private Health
chains Sectors
Handling Expenses:
Insurance Costs:
Customs duties:
Consumers

| 28
TERMS OF SALE

FOB:
FAS:

C&F:
CIF:

| 29
METHODS OF PAYMENT

Cash in Advance:
Open Accounts:
Consignment Sales
Sight Draft:
Time Draft:
Date Draft:
Letter of Credit:

Pro forma financial statements and budgets

Marketing budget:

| 30
RECOMMENDATION

| 31
IMPROVING PRICE AND QUALITY ON THE
DOMESTIC MARKET

Increase competition
Improve the government’s regulatory function.
Financing.
o Increased regular budget.
o Increased fee revenue.
o Donations.
o Collaboration with the domestic pharmaceutical industry.
Structure.
Some areas to consider are as follows:
o Reviewing regulatory procedures and incentives.
o A reorganization of the regulatory authority.
o Cracking down on corruption.
o Making strategic personnel choices.
o Increasing public involvement.
Level the playing field.
Regulatory Approach.
Transparency Approach.
Involving the private sector in quality control.

| 32
IMPROVING PRICE AND QUALITY ON THE
EXPORT MARKET
Encourage contract manufacturing.
Technical Assistance.
Inspections and GMP certification.
Exporting pharmaceutical products.
Investment and Strategy.
TRIPS.
Government support for firms that export.
Investigation into the feasibility of a bioequivalence laboratory.
Investigation of API production.
The API park

API skill.

| 33
Backward integration.

CONCLUSION:

Bibliography

| 34